564 related articles for article (PubMed ID: 16950548)
1. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.
Phelps AL; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2007 Jan; 25(1):34-42. PubMed ID: 16950548
[TBL] [Abstract][Full Text] [Related]
2. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of replicating smallpox vaccine strains in a murine challenge model.
Phelps A; Gates AJ; Hillier M; Eastaugh L; Ulaeto DO
Vaccine; 2005 May; 23(27):3500-7. PubMed ID: 15855008
[TBL] [Abstract][Full Text] [Related]
4. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
5. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection.
Coulibaly S; Brühl P; Mayrhofer J; Schmid K; Gerencer M; Falkner FG
Virology; 2005 Oct; 341(1):91-101. PubMed ID: 16061267
[TBL] [Abstract][Full Text] [Related]
6. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
Abdalrhman I; Gurt I; Katz E
Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine.
Ferrier-Rembert A; Drillien R; Tournier JN; Garin D; Crance JM
Vaccine; 2008 Mar; 26(14):1794-804. PubMed ID: 18336966
[TBL] [Abstract][Full Text] [Related]
8. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
9. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
McCurdy LH; Larkin BD; Martin JE; Graham BS
Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.
Vollmar J; Arndtz N; Eckl KM; Thomsen T; Petzold B; Mateo L; Schlereth B; Handley A; King L; Hülsemann V; Tzatzaris M; Merkl K; Wulff N; Chaplin P
Vaccine; 2006 Mar; 24(12):2065-70. PubMed ID: 16337719
[TBL] [Abstract][Full Text] [Related]
11. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
[TBL] [Abstract][Full Text] [Related]
12. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.
Drexler I; Staib C; Kastenmuller W; Stevanović S; Schmidt B; Lemonnier FA; Rammensee HG; Busch DH; Bernhard H; Erfle V; Sutter G
Proc Natl Acad Sci U S A; 2003 Jan; 100(1):217-22. PubMed ID: 12518065
[TBL] [Abstract][Full Text] [Related]
13. Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.
Ferrier-Rembert A; Drillien R; Meignier B; Garin D; Crance JM
Vaccine; 2007 Nov; 25(49):8290-7. PubMed ID: 17964011
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.
Earl PL; Americo JL; Wyatt LS; Eller LA; Whitbeck JC; Cohen GH; Eisenberg RJ; Hartmann CJ; Jackson DL; Kulesh DA; Martinez MJ; Miller DM; Mucker EM; Shamblin JD; Zwiers SH; Huggins JW; Jahrling PB; Moss B
Nature; 2004 Mar; 428(6979):182-5. PubMed ID: 15014500
[TBL] [Abstract][Full Text] [Related]
15. Substitution of vaccinia virus Elstree by modified vaccinia virus Ankara to test the virucidal efficacy of chemical disinfectants.
Hartnack S; Essbauer S; Truyen U
Zoonoses Public Health; 2008; 55(2):99-105. PubMed ID: 18234028
[TBL] [Abstract][Full Text] [Related]
16. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
17. [Development of a numerically additive combined vaccine against tetanus and smallpox].
Mayr A; Baljer G; Wagner C; Sailer J
Zentralbl Bakteriol Mikrobiol Hyg A; 1985 Apr; 259(2):206-18. PubMed ID: 2990123
[TBL] [Abstract][Full Text] [Related]
18. Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.
Meseda CA; Weir JP
Future Microbiol; 2010 Sep; 5(9):1367-82. PubMed ID: 20860482
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and genetic diversity of the traditional Lister smallpox vaccine.
Garcel A; Perino J; Crance JM; Drillien R; Garin D; Favier AL
Vaccine; 2009 Jan; 27(5):708-17. PubMed ID: 19059294
[TBL] [Abstract][Full Text] [Related]
20. Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.
He Y; Meseda CA; Vassell RA; Merchlinsky M; Weir JP; Weiss CD
Vaccine; 2010 Jan; 28(3):699-706. PubMed ID: 19887133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]